In a groundbreaking development, Tim Becker's lab is on a mission to revolutionize stroke treatment and strive towards achieving a 100% survival rate for patients. Innovative Medical Devices for Ischemic and Hemorrhagic Strokes: Becker and his team are focusing on developing cutting-edge medical devices for both ischemic and hemorrhagic strokes. Ischemic strokes, caused by blood clots in the brain, are currently treated with a clot-busting drug or a catheter to remove the clot. However, existing methods have limitations in effectiveness. Becker's team is working on suction devices designed to grab the entire clot, significantly enhancing treatment outcomes. Novel Approaches for Hemorrhagic Strokes: Hemorrhagic strokes, resulting from a ruptured aneurysm in the brain, pose a significant challenge with only a 15% survival rate. Becker's lab is developing a porous balloon mesh that allows blood flow while promoting vessel healing, potentially increasing survival rates post-stroke. Testing on Simulated Patients: To simulate real-life conditions, Becker's lab has created a lifelike 'patient' with 3D-printed blood vessels and fluid circulation systems. These simulated patients enable rigorous testing and refinement of medical devices in a controlled environment. Addressing Disparities in Health Outcomes: Holly Berns, a Ph.D. student in bioengineering, is leading efforts to tackle racial and gender disparities in stroke treatment. Her groundbreaking prototype, the ATTAC catheter, offers adaptability to different body types, aiming for improved outcomes and higher survival rates. Berns, fueled by personal experiences, is determined to push the boundaries of stroke treatment and achieve better results for all patients. As the medical field continues to evolve, Becker's lab remains at the forefront of innovation, paving the way for a future where stroke survival rates reach new heights.